The past year has seen the reassessment of several antiprotozoal agent
s and anthelmintics, particularly in the immunocompromised patient wit
h intestinal parasitic infection. These advances are reviewed, with em
phasis on the treatment of cryptosporidiosis, microsporidiosis and dis
seminated strongyloidiasis. The emergence of drug resistance in giardi
asis and mass treatment for geohelminths in areas of high endemicity a
re also discussed.